Should Edwards Lifesciences Stock Stay in Your Portfolio Now?

Zacks01-16

Edwards Lifesciences EW is developing the most comprehensive structural heart disease portfolio post the sell-off of the Critical Care wing. The Surgical Structural Heart business is benefiting from ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2503151389?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-16 20:25","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2503151389","market":"us","top_or_hot":-1,"title":"Should Edwards Lifesciences Stock Stay in Your Portfolio Now?","media":"Zacks","content":"<div>\n<p>Edwards Lifesciences EW is developing the most comprehensive structural heart disease portfolio post the sell-off of the Critical Care wing. The Surgical Structural Heart business is benefiting from ...</p>\n\n<a href=\"https://finance.yahoo.com/news/edwards-lifesciences-stock-stay-portfolio-122500230.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should Edwards Lifesciences Stock Stay in Your Portfolio Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould Edwards Lifesciences Stock Stay in Your Portfolio Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-16 20:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/edwards-lifesciences-stock-stay-portfolio-122500230.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Edwards Lifesciences EW is developing the most comprehensive structural heart disease portfolio post the sell-off of the Critical Care wing. The Surgical Structural Heart business is benefiting from ...</p>\n\n<a href=\"https://finance.yahoo.com/news/edwards-lifesciences-stock-stay-portfolio-122500230.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0012050646.USD","symbol_name":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","start_time":0,"source_url":"https://finance.yahoo.com/news/edwards-lifesciences-stock-stay-portfolio-122500230.html","article_id":"2503151389","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503151389","pubTimestamp":1737030300,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Edwards LifesciencesEW is developing the most comprehensive structural heart disease portfolio post the sell-off of the Critical Care wing. The Surgical Structural Heart business is benefiting from the strong adoption of premium surgical technologies worldwide. In TMTT  segment, the increasing global uptake of PASCAL and EVOQUE is highly encouraging. Meanwhile, a volatile macro economy and adverse currency impacts may dent Edwards’ growth.In the past year, this Zacks Rank #3  stock has lost 4.8% against the 7.1% rise of the industryand the 24.4% growth of the S&P 500 composite.The renowned global medical device company has a market capitalization of $41.90 billion. EW’s earnings surpassed estimates in one of the trailing four quarters and matched on three occasions, with the average surprise being 0.78%.Find the latest EPS estimates and surprises on ZacksEarnings Calendar.TMTT Portfolio Holds Potential: Backed by the insights gained from clinical trials and real-world experiences, the ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","EW":"爱德华兹","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","HAE":"美国血液技术","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","BK4139":"生物科技","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","BK4007":"制药","VCYT":"Veracyte Inc","BK4082":"医疗保健设备","HF":"绝对收益主动型ETF-DGA","BK4588":"碎股","BK4198":"医疗保健用品","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","BK4504":"桥水持仓","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","PAHC":"Phibro Animal Health Corporation"},"translate_title":"爱德华兹生命科学股票现在应该留在您的投资组合中吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":1,"PAHC":1,"EW":1,"HAE":1,"HF":1},"content_text":"Edwards Lifesciences EW is developing the most comprehensive structural heart disease portfolio post the sell-off of the Critical Care wing. The Surgical Structural Heart business is benefiting from the strong adoption of premium surgical technologies worldwide. In TMTT (Transcatheter Mitral Triscuspid Therapy) segment, the increasing global uptake of PASCAL and EVOQUE is highly encouraging. Meanwhile, a volatile macro economy and adverse currency impacts may dent Edwards’ growth.\nIn the past year, this Zacks Rank #3 (Hold) stock has lost 4.8% against the 7.1% rise of the industry and the 24.4% growth of the S&P 500 composite.\nThe renowned global medical device company has a market capitalization of $41.90 billion. EW’s earnings surpassed estimates in one of the trailing four quarters and matched on three occasions, with the average surprise being 0.78%.\nFind the latest EPS estimates and surprises on Zacks Earnings Calendar.\nLet’s delve deeper.\nUpsides for EW\nCritical Care Divestment Fuels Structural Heart Opportunities: On Sept. 3, 2024, Edwards completed the sale of its Critical Care product group to Becton, Dickinson and Company for $4.2 billion in an all-cash transaction. Edwards expects this sell-off to enhance its balance sheet flexibility for disciplined investments in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heart failure. The company’s underlying rationale for separating Critical Care aligns with its vision to develop the most comprehensive structural heart disease portfolio. Through its differentiated innovations, Edwards aims to address the large unmet patient needs while extending its global leadership, delivering sustainable growth and increasing shareholder value.\nSurgical Structural Heart, a Promising Business: The business pioneered the innovative RESILIA tissue, which is backed by more than 40 years of the company’s tissue technology leadership. In the third quarter of 2024, the segment’s growth was driven by strong global adoption of Edwards’ premium surgical technologies — INSPIRIS, MITRIS and KONECT. The company continues to see procedure growth globally for many patients treated surgically, including those undergoing complex procedures.\nImage Source: Zacks Investment Research\nEdwards has been expanding the overall body of RESILIA evidence and enrollment for the MOMENTIS clinical trial, studying the durability of RESILIA tissue in the mitral position. Within Heart Failure, the company has released strong 12-month results from its proactive heart failure (HF) pivotal trial, demonstrating significant benefits to patients managed with the Cordella system. As another major development, Edwards closed the acquisition of Endotronix in the third quarter, marking its entry into implantable heart failure management (IHFM).\nTMTT Portfolio Holds Potential: Backed by the insights gained from clinical trials and real-world experiences, the company constructed a strategic portfolio of leading transcatheter technologies to provide both repair and replacement solutions for mitral and tricuspid patients. In the third quarter, the segment achieved a 73% increase from the prior year, driven by the PASCAL system and the continued introduction of the EVOQUE system in the United States and Europe.\nPASCAL’s growing adoption underscores its premium differentiation and the value it delivers to both physicians and patients. Globally, mitral procedures are experiencing double-digit growth and even stronger growth in tricuspid therapy. Meanwhile, Edwards Lifesciences is making strides with the EVOQUE commercial rollout, having successfully activated new sites in both the United States and Europe (other than initial trial centers). During the third quarter, the company achieved approval in the United States for a fourth and larger size EVOQUE valve — 56 millimeters.\nConcerns for Edwards\nMacro Concerns Weigh on the Bottom Line: The global economy continues to experience volatility and disruptions, including inflation and factors influencing overall economic stability and the political environment relating to health care.  Additionally, any significant increases in the cost of raw materials, supply constraints stemming from geopolitical complications, regulatory changes or otherwise, could weigh heavily on the company’s operating results. Post-pandemic, the business has been experiencing staffing shortages within the hospital systems and a surge in medical supply expenses, which is putting significant pressure on the margins of medical device companies like Edwards.\nForeign Exchange Headwinds: Foreign exchange is a major headwind for Edwards because a considerable percentage of its revenues come from outside the United States. The unfavorable currency fluctuations have adversely impacted the company’s gross margin over the past few quarters. Foreign exchange rates lowered third-quarter 2024 adjusted sales growth by 70 basis points, or $7.9 million, from a year ago.\nEW’s Estimate Trend\nThe Zacks Consensus Estimate for Edwards’ 2024 earnings per share (EPS) has remained constant at $2.56 in the past 30 days.\nThe Zacks Consensus Estimate for the company’s 2024 revenues is pegged at $5.89 billion. This suggests a 1.8% fall from the year-ago reported number.\nTop MedTech Picks\nSome better-ranked stocks in the broader medical space are Veracyte VCYT, Haemonetics HAE and Phibro Animal Health PAHC.\nVeracyte has estimated 2024 earnings growth rate of 137.3% compared with the industry’s 14.9%. Veracyte’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 520.6%. Its shares have risen 63% compared to the industry’s 7.1% growth in the past year.\nVCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nPhibro Animal Health, carrying a Zacks Rank #2 (Buy) at present, has an estimated earnings growth rate of 36.1% for fiscal 2025 compared with the industry’s 11.9%. Shares of the company have risen 83% compared with the industry’s 9.3% growth over the past year. PAHC’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 25.47%.\nHaemonetics, carrying a Zacks Rank #2 at present, has an estimated fiscal 2025 earnings growth rate of 15.9% compared with the industry’s 11.9%. Shares of the company have lost 9.1% against the industry’s 9.3% growth. HAE’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, with the average surprise being 2.82%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nEdwards Lifesciences Corporation (EW) : Free Stock Analysis Report\nHaemonetics Corporation (HAE) : Free Stock Analysis Report\nPhibro Animal Health Corporation (PAHC) : Free Stock Analysis Report\nVeracyte, Inc. (VCYT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2503151389"}